Non-invasive Diagnostics

bioAffinity Technologies announced the completion of a public offering, generating $4.8 million in gross proceeds. The offering included shares of common stock and pre-funded warrants. WallachBeth Capital, LLC served as the placement agent. bioAffinity focuses on non-invasive cancer diagnostics, including CyPath® Lung, a Laboratory Developed Test for early lung cancer detection. The company addresses the growing precision diagnostics market with a focus on improving patient outcomes through early diagnosis. The announcement contains forward-looking statements subject to risks detailed in SEC filings.